Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: A retrospective study

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Barisik, Nagehan O ^a   Bozkurt, Suheyla ^b   Gumus, Mahmut ^a   Kaygusuz, Isik ^b   Karadayi, Nimet ^a   Bas, Emine ^b   Bayik, Mahmut ^b   Tecimer, Tulay ^b  

^a Kartal Research and Education Hospital   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P53; PTGS2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; REED STERNBERG CELL; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ADULT; CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; PROGNOSIS; REED-STERNBERG CELLS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957985081     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-19     Document Type: Article

References (29)

1. Ioachim's HL. Medeiros Lymph Node Pathology. classical Hodgkin lymphoma 2009, 306-324. Philadelphia: Lippincott Williams @ Wilkins, Murphy J, McGough J, 4.
2. Stein H. Hodgkin lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 321-334. Lyon: IARC Pres, Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, ThieleJ, Vardiman JW.
3. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004, 96:305-315.
4. Wang J, Taylor CR. Apoptosis and cell cyle-related genes and proteins in classical Hodgkin lymphoma. Appl Immunohistochemistry-Mol Morphology 2003, 11(3):206-213.
5. Rongen MM, Roers A, Küppers R, Rajewsky K, Hansman ML. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg Cells in Hodgkin's disease. Neoplasia 1999, 94(5):1755-1760.
6. Rassidakis GZ, Medeiros JL, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosisi in patients treated with ABVD or equivalent regimes. Blood 2002, 100(2):3935-3941. 10.1182/blood.V100.12.3935, 12433696.
7. Ohsawa M, Fukushima H, Ikura Y, Inoue T, Shi{dotless}rai{dotless} N, Sugama Y, et al. Expression of cyclooxcygenase-2 in Hodgkin's lymphoma:Its role in cell proliferation and angiogenesis. Leuk Lymphoma 2006, 47(9):1863-1871. 10.1080/10428190600685442, 17064999.
8. Tilley S, Coffman TM, Koller BH. Mixeded message: modulation of inflamtion and immune responses by prostaglandins and trombaxanes. J Clin Invest 2001, 108:15-23. 209346, 11435451.
9. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The Cyclooxygenas -2 inhibitor celecoxib is a potent preventive and therapeutic agent in min mouse model of adenomatous polyposis. Cancer Res 2000, 60:5040-5044.
10. Gi{dotless}ovannucci{dotless} E, Egan KM, Hunter DJ, Stampfer MJ, Coldi{dotless}tz GA, Willet WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614. 10.1056/NEJM199509073331001, 7637720.
11. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase -2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002, 62:1676-1681.
12. Shamma A, Yamamoto H, Doki Y, Okami J, Konda M, Fujiwara Y, Yano M, et al. Up-regulation of cyclooxygenase-2 in squamos carcinogenesis of the esophagus. Clin Cancer Res 2000, 6:1229-1238.
13. Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, et al. Expression of cyclooxygenase-2 in adenocarcinomas of the uterin cercix and its relation to angiogenesis and tumor growth. Gynecol Oncol 2004, 95:523-529. 10.1016/j.ygyno.2004.08.002, 15581957.
14. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005, 11:1618-1628. 10.1158/1078-0432.CCR-04-1696, 15746067.
15. Hussain PS, Haris CC. P53 mutation spectrum and load:the generation or hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999, 428:23-32.
16. Gupta RK, Norton AJ, Thompson IW, Lister TA, Bodmer JG. P53expression in Reed -Sternberg cells of Hodgkin's disease. Br J Cancer 1992, 66:649-652. 1977425, 1419601.
17. Gallo O, Schiavone N, Papucci L, Sardi I, Magnelli L, Franchi A, Masini E, Capacioli S. Down-regulation of nitric oxide Synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 2003, 163:723-732. 1868223, 12875991.
18. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by P53. J Biol Chem 1999, 274(16):10911-10915. 10.1074/jbc.274.16.10911, 10196169.
19. Maggi{dotless}o E, Stekelenburg E, Berg A, Poppema S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Ebstein - Barr virus. Int J Cancer 2001, 94:60-66. 10.1002/ijc.1438, 11668479.
20. Shigemasa K, Ti{dotless}an X, Gu L, Shi{dotless}royama Y, Nagai{dotless} N, Ohama K. Expression of cylooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003, 22:99-105.
21. Yu HP, Xu SH, Liu L, Shi LY, Cai XK, Lu WH, Lu B, et al. Cylooxygenase-2 expression in squamous displasia and squamous cell carcinoma of the esophagus. Cancer Lett 2003, 198:193-201. 10.1016/S0304-3835(03)00340-9, 12957358.
22. Sinicrope FA, Lemoine M, XI L, Lynch PM, Clearly KR, Shen Y, Frazier M. Reduced expression of cylooxygenase-2 proteins in hereditery nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterol 1999, 117:350-358.
23. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58:362-366.
24. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cylooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol 1994, 107:1183-1188.
25. Sun Y, Tang M, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytocrome c-depent apoptotic pathway in human colon cancer cells. Cancer Res 2002, 62:6323-6328.
26. Sorensen HT, Friis S, Nergard B, Mellemkjaer L, Blot WJ, McLaugglin JK, Ekbom A, Baron JA. Risk of cancer in large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692. 10.1038/sj.bjc.6600945, 2377131, 12771981.
27. Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk lymphoma 2004, 45:1395-1399. 10.1080/10428190310001654032, 15359639.
28. Hsu SM, Hsu P, Lo SS, Wu KK. Expression of prostaglandin H synthase (Cyclooxygenase) in Hodgkin's mononuclear and Reed-Sternberg cells. Am J Pathol 1988, 133:5-12. 1880645, 3140669.
29. Vogelstein B, Lane D, Levine AJ. The p53 tumour-supressor gene integrates numerous signals that control cell life and death. As when a highly connected node in the internet breaks down the disruption of p53 has severe consequences. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.